Information on fracture site and radiological


Information on fracture site and radiological

evaluation was, however, not systematically available. Outcome measures The outcome measures of the study were MPR and persistence. MPR was defined as the duration of all filled prescriptions divided by the follow-up Dorsomorphin period. Persistence was measured by the time from initiation of therapy to discontinuation. As required for persistence analysis, a limit on the number of days allowed between refills, the permissible gap (PG), was prespecified. Patients who stopped their treatment for a duration longer than the PG were considered to have selleck chemicals discontinued, even if they subsequently restarted treatment. In many previous studies, the PG applied to weekly bisphosphonates was specified empirically at 30 days [9, 26–28]. Cramer et al. [5] recently proposed a less arbitrary method based on the pharmacological properties of the drug and the treatment situation in which the PG definition should take into account the maximum allowable period for which patients could go untreated without anticipating reduced or suboptimal outcomes. As specified in the product labelling, the recommended acceptable dosing window for monthly ibandronate (21 days) is 15 days longer than that of weekly bisphosphonates (6 days). For this reason, a prespecified PG of 45 days for the monthly regimen and of 30 days for the weekly regimen was considered acceptable,

as previously implemented in a US database analysis [29]. We also performed a sensitivity analysis in order to test the influence Avapritinib nmr of the definition of PG on the persistence results in which an identical PG of 30, 45 or 60 days was allowed for both formulations. Statistical analysis The demographic and clinical characteristics of patients included in the two cohorts were compared using the χ 2 test or Fisher’s exact test for categorical variables and the Kruskal–Wallis test for continuous

variables. Persistence rates were evaluated using Kaplan–Meier survival analysis and compared between the two Ketotifen cohorts using the log-rank test in a Cox proportional hazards model. For MPR, the two cohorts were described by mean MPR values and by distribution of patients across MPR classes. This analysis was performed on the entire study population. Since the profiles of patients in the weekly and monthly cohorts were potentially different and confounding factors could thus contribute to the difference in persistence and in MPR between the two cohorts, these were taken into account by constructing a propensity score [30]. This score included all demographic, clinical and treatment variables recorded in the database and was calculated using multivariate logistic regression. Each patient was attributed a propensity score that represented the probability of receiving monthly rather than weekly bisphosphonate treatment with respect to the pattern of potential confounding factors presented.

Comments are closed.